Literature DB >> 23871415

Sirtuin-3 (SIRT3) expression is associated with overall survival in esophageal cancer.

Yue Zhao1, Huichai Yang, Xiaoling Wang, Ruixing Zhang, Cuiju Wang, Zhanjun Guo.   

Abstract

Sirtuin-3 (SIRT3) was immunostained in 94 samples of esophageal cancer tissues and semiquantified using the HSCORE method to evaluate the predictive value of SIRT3 expression levels on esophageal cancer outcome. The relationship between SIRT3 expression and the 5-year survival rate of postoperational esophageal cancer patients was assessed with the Kaplan-Meier method. High expression of SIRT3 is associated with a shorter survival time in esophageal cancer patients, as shown by the log-rank test (P = .007), and the level of SIRT3 expression was identified as an independent predictor for esophageal cancer outcome using Cox proportional hazards model analysis (relative risk, 2.061; 95% confidence interval, 1.050-4.046; P = .036). SIRT3 expression was associated with esophageal cancer outcome. The analysis of SIRT3 levels can help in the identification of patient subgroups that are at high risk for poor disease outcomes.
© 2013.

Entities:  

Keywords:  Esophageal cancer; Predictor; SIRT3; Survival

Mesh:

Substances:

Year:  2013        PMID: 23871415     DOI: 10.1016/j.anndiagpath.2013.06.001

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  18 in total

1.  A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells.

Authors:  Turki Y Alhazzazi; Pachiyappan Kamarajan; Yanli Xu; Teng Ai; Liqiang Chen; Eric Verdin; Yvonne L Kapila
Journal:  Anticancer Res       Date:  2016-01       Impact factor: 2.480

2.  4'-Bromo-resveratrol, a dual Sirtuin-1 and Sirtuin-3 inhibitor, inhibits melanoma cell growth through mitochondrial metabolic reprogramming.

Authors:  Jasmine George; Minakshi Nihal; Chandra K Singh; Nihal Ahmad
Journal:  Mol Carcinog       Date:  2019-07-10       Impact factor: 4.784

3.  Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway.

Authors:  C-L Song; H Tang; L-K Ran; B C B Ko; Z-Z Zhang; X Chen; J-H Ren; N-N Tao; W-Y Li; A-L Huang; J Chen
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

4.  Pro-Proliferative Function of Mitochondrial Sirtuin Deacetylase SIRT3 in Human Melanoma.

Authors:  Jasmine George; Minakshi Nihal; Chandra K Singh; Weixiong Zhong; Xiaoqi Liu; Nihal Ahmad
Journal:  J Invest Dermatol       Date:  2015-12-29       Impact factor: 8.551

5.  SIRT3 is a novel prognostic biomarker for esophageal squamous cell carcinoma.

Authors:  Shu-Mei Yan; Xian Han; Pei-Jin Han; He-Mu Chen; Li-Yun Huang; Yong Li
Journal:  Med Oncol       Date:  2014-07-09       Impact factor: 3.064

6.  SIRT3 Enhances Glycolysis and Proliferation in SIRT3-Expressing Gastric Cancer Cells.

Authors:  Yang Cui; Lili Qin; Jing Wu; Xuan Qu; Chen Hou; Wenyan Sun; Shiyong Li; Andrew T M Vaughan; Jian Jian Li; Jiankang Liu
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

Review 7.  Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer.

Authors:  Y Chen; L L Fu; X Wen; X Y Wang; J Liu; Y Cheng; J Huang
Journal:  Cell Death Dis       Date:  2014-02-06       Impact factor: 8.469

Review 8.  SIRT3: Oncogene and Tumor Suppressor in Cancer.

Authors:  Margalida Torrens-Mas; Jordi Oliver; Pilar Roca; Jorge Sastre-Serra
Journal:  Cancers (Basel)       Date:  2017-07-12       Impact factor: 6.639

Review 9.  Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease.

Authors:  Aneesa Ansari; Md Shahedur Rahman; Subbroto K Saha; Forhad K Saikot; Akash Deep; Ki-Hyun Kim
Journal:  Aging Cell       Date:  2016-09-29       Impact factor: 9.304

10.  Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.

Authors:  Na-Na Tao; Hong-Zhong Zhou; Hua Tang; Xue-Fei Cai; Wen-Lu Zhang; Ji-Hua Ren; Li Zhou; Xiang Chen; Ke Chen; Wan-Yu Li; Bo Liu; Qiu-Xia Yang; Sheng-Tao Cheng; Li-Xia Huang; Ai-Long Huang; Juan Chen
Journal:  Oncotarget       Date:  2016-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.